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ABSTRACT
Circulating tumor cells (CTCs) are emerging as rare but clinically significant 
non-invasive cellular biomarkers for cancer patient prognosis, treatment selection, 
and treatment monitoring. Current CTC isolation approaches, such as immunoaffinity, 
filtration, or size-based techniques, are often limited by throughput, purity, large 
output volumes, or inability to obtain viable cells for downstream analysis. For all 
technologies, traditional immunofluorescent staining alone has been employed to 
distinguish and confirm the presence of isolated CTCs among contaminating blood 
cells, although cells isolated by size may express vastly different phenotypes. 
Consequently, CTC definitions have been non-trivial, researcher-dependent, and 
evolving. Here we describe a complete set of objective criteria, leveraging well-
established cytomorphological features of malignancy, by which we identify large 
CTCs. We apply the criteria to CTCs enriched from stage IV lung and breast cancer 
patient blood samples using the High Throughput Vortex Chip (Vortex HT), an 
improved microfluidic technology for the label-free, size-based enrichment and 
concentration of rare cells. We achieve improved capture efficiency (up to 83%), 
high speed of processing (8 mL/min of 10x diluted blood, or 800 μL/min of whole 
blood), and high purity (avg. background of 28.8±23.6 white blood cells per mL of 
whole blood). We show markedly improved performance of CTC capture (84% positive 
test rate) in comparison to previous Vortex designs and the current FDA-approved 
gold standard CellSearch assay. The results demonstrate the ability to quickly collect 
viable and pure populations of abnormal large circulating cells unbiased by molecular 
characteristics, which helps uncover further heterogeneity in these cells.
INTRODUCTION
Circulating tumor cells (CTCs) are cancer cells that 
have been shed from a tumor into the bloodstream and 
play a major role in metastasis. The relative number of 
CTCs is predictive of patient prognosis and treatment 
efficacy [1, 2]. Moreover, there is growing interest in 
using CTCs as non-invasive cellular markers of cancer 
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genotypic and phenotypic changes for both clinical and 
research applications, and so it is important to be able to 
isolate and analyze CTCs from a vial of patient blood. 
Nevertheless, CTCs are extremely rare and are found at 
concentrations as low as 1-10 CTCs/mL of whole blood in 
a background of millions of white blood cells (WBCs) and 
billions of red blood cells (RBCs).
Many current technologies employ affinity-based 
capture methods, using antibodies or aptamers that 
bind to cell surface markers [3]. The CellSearch system 
(Janssen Diagnostics) is the current gold standard 
prognostic tool which makes use of a ferromagnetic 
immunoaffinity assay that targets CTCs using probes 
against epithelial cell adhesion marker (EpCAM) [4, 
5]. Despite achieving high capture efficiencies using 
cultured cell lines, it remains challenging to capture 
heterogeneous patient sample CTCs, many of which are 
now known to undergo an epithelial-to-mesenchymal 
transition (EMT) which may involve downregulation of 
target epithelial cell surface markers [6, 7]. Alternative 
technologies are emerging which target cell size as an 
alternative biophysical marker for CTCs. For example, 
the ISET [8-10] and ScreenCell [11, 12] devices make 
use of porous filters to separate larger CTCs from the 
smaller RBCs and WBCs, and more recent microfluidic 
approaches further refine the interaction between cells and 
microfabricated structures [13, 14], including the use of 
microchannel constrictions [15], micropillar arrays [16], 
and other microfilter variations [17-19]. Nevertheless, 
direct filtration approaches are prone to clogging due to 
intrinsic interactions between sticky cancer and blood cells 
and filter surfaces, and cells may be difficult to release for 
further downstream analysis.
Continuous flow microfluidics has emerged as a 
promising technology for the reduced-contact isolation and 
extraction of viable CTCs by size, such as hydrodynamic 
filtration [20, 21] or deterministic lateral displacement 
[22, 23]. Recent advances in inertial microfluidics have 
offered a more rapid platform through which cells may 
be sorted by size, as fluidic forces generated from high 
flow rates scale strongly with cell size [24, 25]. Notable 
technologies with high capture efficiencies include the 
use of shear gradient lift forces in expansion-contraction 
microchannels [26-28], Dean flow fractionation (DFF) 
in spiral microfluidic chips (Clearbridge Biomedics) [29, 
30], and inertial focusing prior to WBC negative depletion 
using immunomagnetic beads (CTC-iChip) [31]. Still, 
current techniques have been hindered by scalability, low 
sample purity, and dilute output sample volumes which 
require additional cell concentration steps.
Although size-based isolation and negative 
depletion approaches may acquire subpopulations of cells 
that have undergone EMT or other trans-differentiation 
processes, collected cells can be difficult to identify with 
commonly used stains (e.g. cytokeratins, CK) optimized 
for cells of epithelial origin. Studies have found irregular 
CTC expression profiles in which epithelial (CK, 
EpCAM), mesenchymal (vimentin, N-cadherin), or 
potentially either both or neither markers are expressed 
[32-34]. Additionally, non-specific binding of probes 
may result in cross-reactivity and cause difficulties 
in proper cell identification. Although the CellSearch 
CellTracks Analyzer II semi-automated system aids in 
CTC identification, identification is dependent solely 
on CK expression, and there remains variability of cell 
classification between trained operators [4, 5]. Finally, 
variability of staining protocols, antibody clones between 
vendors, and imaging setups causes conflicting definitions 
of CTCs. A more general, standardized staining and 
classification approach is required, which takes into 
account cells that are negatively- or doubly-stained for 
standard markers. Cytomorphological characteristics, such 
as abnormal cell size and large nuclear-to-cytoplasmic 
(N:C) ratios, are also indicators of malignancy or 
hematopoietic origins [35] that may be factored in with 
high quality imaging for cell identification. Because 
of differences in implementing immunofluorescence 
staining and counting protocols between labs, an ideal 
classification approach should be rigorously described 
and demonstrated with galleries of images and detailed 
training documents.
We have previously described the Vortex Chip [36], 
a simple microfluidic device with rectangular reservoirs 
which generate stable laminar fluid microvortices at 
high flow rates to passively trap, purify, and concentrate 
large CTCs from blood or other body fluids [37]. Despite 
achieving high purity, the previous device was limited 
by low capture efficiency (~20%) and a high but un-
optimized throughput for processing 10x diluted blood (4 
mL/min). Here, we introduce the High Throughput Vortex 
Chip (Vortex HT), which demonstrates markedly increased 
processing speed and tunable capture efficiency achieved 
by reflowing of the sample waste. We also implement 
objective, standardized classification criteria which are 
explained and demonstrated with detailed protocols and 
image galleries from new clinical studies, and use these 
criteria to compare device performance directly with 
previous designs and the gold standard for the same 
cancer patients. Vortex HT outperforms previous Vortex 
designs and the gold standard CellSearch system over a 
range of criteria, yielding a flexible and high-performance 
technology for obtaining CTCs for clinical and research 
purposes.
RESULTS
Design iterations toward Vortex HT
While previous work has assessed the effect of 
sample concentration, biophysics, and other extrinsic 
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factors on the efficiency of Vortex trapping [36], the Vortex 
HT design—used throughout the study (Figure 1A)—was 
established after several design iterations (Supplementary 
Figure 1) which explored the intrinsic device layout and 
maximized the capture potential and throughput of Vortex 
trapping. First, the long straight upstream channel of the 
original Vortex Chip was found to be unnecessary for 
trapping. While a 10,000 μm upstream length was initially 
thought to provide inertial cell focusing toward the two 
lateral side walls and in closer proximity to the vortex 
region to improve capture, COMSOL software simulations 
demonstrated that the fluid flow profile fully develops 
within a relatively shorter 500 μm minimum distance 
(Supplementary Figure 2), suggesting that sufficient shear 
gradient lift forces are achievable over shorter distances 
for cells already present near walls. Tests revealed a 
peak efficiency with a 500 μm upstream distance before 
reservoirs, below which efficiency decreased. A 1000 μm 
Figure 1: Microfluidic device design and performance. A. The High Throughput Vortex Chip (Vortex HT) is parallelized with 
2x more parallel channels and 1.5x more serial reservoirs in each channel than the previous Vortex Chip design. At high flow rates, 
microvortices develop in each reservoir and trap larger cancer cells while allowing smaller RBCs and WBCs to either pass through or 
transiently enter vortices. B. With the same processing time, Vortex HT yields ~1.6x higher capture efficiency of MCF7 breast cancer cells 
while maintaining comparable purity (n = 3 trials) relative to the Vortex Chip. C. Sample flow-through may be collected and repeatedly 
processed through multiple cycles to increase cell capture with a tradeoff of slightly diminished sample purity. D. MCF7 cells processed 
through Vortex HT maintained high relative viability compared with cells not processed through the device. E. MCF7 cells released into a 
well-plate are able to grow and proliferate over the course of 4 days. Scale bar represents 40 μm.
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straight channel distance between reservoirs was chosen 
to achieve a balance between high efficiency and purity 
(Supplementary Figure 2D). Accordingly, replacement 
of the long straight upstream focusing channel in the 
Vortex Chip with serial 1000 μm spaced reservoirs was 
found to improve cell capture. High fluidic resistance and 
risk of device failure and delamination limited further 
serialization of reservoirs, restricting the design to 12 
reservoirs per channel. Next, parallelization from 8 to 16 
channels enabled a 2X faster flow rate while maintaining 
the same Reynolds number, the ratio of inertial to 
viscous forces in the flow, necessary for capture. When 
characterizing trapping from a polydisperse solution 
of deformable PDMS beads, Vortex HT demonstrates 
selective enrichment for particles greater than ~13 μm 
(Supplementary Figure 3).
Device performance with cell lines
With the reduced time to process a sample using 
Vortex HT, saved time may be used to reprocess the fluid 
waste from the first trapping cycle to achieve higher 
capture efficiency for cancer cells. In the same processing 
time as the Vortex Chip, Vortex HT recovers cells at 1.6x 
higher efficiency using 2 cycles of processing (Figure 1B) 
while maintaining high sample purity (>80%). Recovery is 
further enhanced by multiple rounds of reprocessing (with 
a trade-off of increased run time), resulting in up to 84% 
cumulative efficiency after 7 processing cycles of 4 mL 
of 10x diluted blood spiked with 300 MCF7 cells (Figure 
1C). Interestingly, taking into account the remaining 
non-captured cells that are infused through the device, 
the adjusted efficiency per cycle was comparable for all 
cycles (avg. 22.8% ± 3.2%), suggesting that the entry 
and maintenance of cells in vortex traps is a probabilistic 
random process which may follow Poisson statistics. 
Consequently, sample reprocessing is reproducible 
between cycles and devices (Supplementary Figure 4). The 
captured cells remain viable and may be collected directly 
off-chip—in a concentrated ~150 μL volume per cycle—
and cultured for over 4 days (Figure 1D-1E). Viability 
from Vortex HT remained even throughout the study (avg. 
83.9% ± 4.0%, with an avg. 8.8% ± 1.8% lower viability 
from the control) and slightly increased by day 4, which 
may be due to the increase in number of proliferated cells. 
Figure 2: Immunofluorescent staining characteristics for identifying CTCs. A. Collected cells were classified according to 
immunostains against CK (green) and CD45 (red), and DNA stained with DAPI (blue). In general, CTCs were defined as either CK+/
CD45-/DAPI+ or only DAPI+ with a large nucleus (>9 μm) and N:C ratio (>0.8). Each cell was compared with the table’s criteria in the 
order listed until the characteristics matched. Scale bars represent 10 μm. B. MCF7 cells, used as a staining control, stained strongly for 
CK and negative for CD45. C. Most WBCs stained for CD45-TRITC but negative for CK. Monocytes and lymphocytes were consistently 
stained strongly whereas granulocytes exhibited weaker CD45 signals. D. CTCs typically stained weakly or negatively for CK. E. Several 
cells stained double-positive for both CD45 and CK. Additional staining of the collected cells with CD66b-AF647 confirmed the cells 
as activated granulocytes. F. Large CK-/CD45- cells with high N:C ratios were present in collected samples and defined as CTCs by our 
criteria. [All scale bars in (B-F)]represent 20 μm.
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CTC classification criteria
Having cells freely released into solution and 
collected on optimized optical substrates without 
interfering bound beads allows for high quality 
fluorescence and brightfield imaging that reveals 
morphologies unique to CTCs. Based on standard CK and 
CD45 immunostaining and morphological features that are 
diagnostic in cytopathology, a set of criteria was developed 
to classify cells (Figure 2A), based on both existing 
methods [35, 38, 39] and observations of cell populations 
captured from healthy donor samples using Vortex HT. 
Classifications were comprised of 3 categories: debris, 
WBCs, or CTCs. In general, debris was characterized by 
irregular, jagged shapes or dark outlines under bright-field 
microscopy. Aside from the clear distinctions of CTCs as 
CK+/CD45-/DAPI+ (Figure 2B, 2D) and WBCs as CK-/
CD45+/DAPI+ (Figure 2C), incidences arise in which 
cells may be doubly-stained (CK+/CD45+/DAPI+) or 
only DAPI+. Staining with CD66b confirmed that doubly-
stained cells corresponded to activated granulocytes 
(Figure 2E), and were thus classified as WBCs. For 
instances in which cells stained only DAPI+, WBCs were 
distinguished by lobular or segmented granulocytic nuclei, 
small nuclei (<9 μm), and/or small N:C ratios, defined in 
this study as the imaged area of the nucleus to the area 
Figure 3: Enumeration of patient CTCs. A. More CTCs/mL of whole blood were found in stage IV lung (n = 15) and breast 
(n = 22) cancer blood samples than in age-matched healthy samples (n = 10). Based on the maximum count for all healthy samples, 
a minimum threshold of 1.25 CTCs/mL of whole blood (dotted green line) was set to define samples as CTC-positive. Using such a 
threshold, approximately 80% and 86% of lung and breast cancer samples, respectively, were found positive for CTCs. B. Representative 
immunofluorescence images of CTCs and WBCs collected from Vortex HT. Scale bars represent 20 μm. C. The purity of collected CTCs 
varied between samples and averaged ~20%. Healthy samples exhibited very low purity due to the few collected cells which were classified 
as CTCs. D. The absolute number of collected WBCs was relatively low as well and was present in all processed samples. 
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of the surrounding cytoplasm. CTCs were primarily 
characterized morphologically by a large nucleus (> 9 μm) 
and large N:C ratio (Figure 2F). Detailed explanations of 
cell classifications with accompanying image galleries 
and training worksheets are included as Supplementary 
Material. 
Device performance with clinical samples
A total of 22 breast, 15 lung, and 10 age-
matched healthy blood samples were used in the study 
(Supplementary Figure 5, Supplementary Table 1). 
The median age was 66 years (range 37-91), and the 
majority of cancer patients (36/37) were undergoing 
treatment at the time of draw. Using the classification 
criteria, more CTCs were found in lung (mean: 5.3 CTCs/
mL, range: 0.5-24.2 CTCs/mL) and breast (mean: 5.4 
CTCs/mL, range: 0.75-23.25 CTCs/mL) cancer samples 
than in healthy controls (mean: 0.56 CTCs/mL, range: 
0-1.25 CTCs/mL) (Figure 3A). A low number of cells 
were characterized as CTCs in healthy samples, with a 
maximum count of ~1.25 CTCs/mL, which is lower than 
that found from previous techniques [36] and suggests a 
higher achieved specificity using a combination of staining 
and morphological criteria. Using this baseline value as a 
threshold, approximately 80% and 86% of lung and breast 
cancer samples, respectively, were found to be positive 
for CTCs. Additionally, although lower than tests with 
cell lines, the purity of cancer blood samples remained 
quite high (avg. 19.8% ± 13.9%, Figure 3C), and up to an 
order of magnitude higher than competing technologies 
such as the CTC-iChip [40]. Moreover, the low absolute 
number of captured WBCs in cancer samples (avg. 187 ± 
164, Figure 3D) represents an approximately 104-105 fold 
depletion, which enables greater signal-to-noise results 
in downstream analyses that are limited by the presence 
of interfering wild-type cells. Interestingly, the absolute 
number of WBCs appears to reveal a baseline value 
below 200 cells in all samples, with few outliers (4 lung 
and 6 breast samples), although it is unclear if the outliers 
are due to unique patient states which may magnify the 
quantity of WBCs captured in Vortex HT.
Captured CTCs displayed varying levels of CK 
expression, with 40.8% of total CTCs not expressing CK at 
all (Figure 4A, 4B). Interestingly, this percentage was not 
reflected at the individual patient level, which exhibited 
a wide range of CK-/DAPI+ CTCs with percentages per 
Figure 4: Immunofluorescent profiles of patient CTCs. A. CTCs collected from each patient sample were composed of both CK-
positive (green) and CK-negative (DAPI+ only, blue) subpopulations. B. Representative images of CK-/DAPI+ and CK+/DAPI+ stained 
CTCs. Scale bar represents 20 μm. C. After traditional CK staining (left bar), cells immunostained for epithelial (EpCAM and CK, green) 
and mesenchymal (VIM, orange) markers (right bar) exhibited diverse variations of all combinations, including expression of both EMT 
markers or neither. The majority of cells were VIM-/CK+/EpCAM+/DAPI+ or VIM-/CK-/EpCAM-/DAPI+. D. Representative images of 
cells which express mesenchymal markers, epithelial markers, neither, or both. Scale bar represents 20 μm. 
Oncotarget12754www.impactjournals.com/oncotarget
patient ranging between 8.7-100% (mean 49.0 ± 24.2%). 
To explore the nature of CK- CTCs, some samples were 
additionally stained for EMT markers using antibodies 
against Vimentin (VIM), N-Cadherin (NCAD), and 
EpCAM (Figure 4C). A small fraction of CK-/DAPI+ cells 
(12.5%) stained positive for VIM/NCAD, representing 
an average 6% of all CTCs collected. Additionally, an 
average of 32.7% of CK+/DAPI+ cells stained positive 
for both epithelial and mesenchymal markers, representing 
an average 17% of all CTCs. Nevertheless, a large 42% 
of CTCs were still negative for all EMT markers and 
only stained positive for DAPI, suggesting that additional 
staining may not significantly supplement standard CK 
stains and cytomorphological characterization as outlined 
in Figure 2.
Comparison of Vortex HT with other technologies
Vortex HT enriched for a larger number of CTCs 
than the Vortex Chip in all 7 lung and 7 breast cancer 
patient samples tested, using the same volume of sample 
and same processing time for each device (Figure 5A). 
Notably, the numbers of CTCs captured with Vortex HT 
correlated with the number of CTCs isolated with the 
Vortex Chip (R2 =0.92, slope=1.44). That is, samples 
with larger CTC numbers captured by Vortex Chip had 
concomitantly larger capture numbers by Vortex HT. These 
results also demonstrated the chip-to-chip concordance 
of this processing approach, which suggests minimal 
variation induced by the capture technology itself. For 
13 cancer patient samples tested with CellSearch, Vortex 
HT found 85% positive for CTCs above a healthy patient 
cut-off whereas CellSearch found only two samples 
(15%) positive above the healthy patient cut-off value 
for that system (Figure 5B-5C). Moreover, the number 
of CTCs captured in these two samples (breast sample 
no. 5 and 6, Figure 5B) were markedly different between 
CellSearch and Vortex HT, which is likely due to the 
differing selection parameters of EpCAM expression 
with CK positivity versus cell size and a combination 
of immunofluorescence and morphological features. No 
CTCs were detected from lung samples by CellSearch, 
which may be due their reduced expression of EpCAM, 
and supports the fact that CellSearch is only FDA 
approved for breast, prostate, and colon cancer blood 
samples. Two other samples (starred, Figure 5B) exhibited 
issues with the CellSearch instrument run by Quest 
Diagnostics, which displayed the error “Machine aborted 
sample during run”, and were deemed as uninterpretable 
for CTCs by the test system. 
Leukemia case
One healthy donor self-reported diagnosis with 
chronic myelogenous leukemia (CML) 20 days after 
having blood drawn for the study, and this patient 
was removed from the analysis of healthy samples. 
Interestingly, very large cytomorphologically atypical 
WBCs were found after processing with Vortex HT, before 
the patient was treated (Supplementary Figure 6). The cells 
were characterized by a range of N:C ratios, but all were 
over 20 μm in diameter and CD45+/DAPI+/CK-/CD66b-. 
An additional sample of blood was later acquired from 
the same patient during treatment. Complete blood counts 
(CBCs) of the patient showed a high concentration of 
WBCs (40.9 K/μL), far above the normal range expected 
in a healthy patient (4-11 K/μL), and later decreased to 3.1 
K/μL while under treatment (Supplementary Figure 6C). 
In a similar trend, fewer atypical WBCs were captured 
from Vortex HT in the second draw. No such atypical 
white blood cells were seen in healthy donor samples, 
nor in lung or breast cancer patient samples, which may 
suggest the utility for Vortex HT as a general approach 
to enrich for other large circulating cells useful for the 
detection and analysis of other diseases.
DISCUSSION
The simple geometry of Vortex HT, consisting 
only of straight microchannels and rectangular trapping 
regions, enables straightforward device fabrication and 
sample processing procedures. With minimal pretreatment 
steps that may damage cells, a vial of blood (~8 mL) may 
be processed in 2 cycles within a short ~20 min period, 
yielding demonstrably higher CTC counts in cancer 
patient specimens over healthy blood and a higher positive 
success rate compared with CellSearch. CellSearch found 
just one breast cancer sample above its defined 5 CTCs per 
7.5 mL threshold that defines patients with poor prognosis 
and shorter survival time, which may suggest that the 
other samples (from patients undergoing treatment) were 
exhibiting low progression. While it is unclear if the 
baseline presence of cells classified as CTCs in healthy 
samples from Vortex HT arise from epithelial cell shedding 
from the blood draw puncture, nonspecific staining, or a 
baseline level normally found in the blood stream, the 
relatively low 1.25 CTCs/mL threshold still distinguished 
many patients as positive for CTCs. The consistent counts 
above the threshold from cancer samples may implicate 
Vortex HT as a more sensitive tool for detecting a diverse 
set of CTCs, which may yield broader distinctions in 
patient prognoses than CellSearch, but will first require 
longer-term studies with regular patient follow-up. 
In relation to other competitive inertial microfluidic 
technologies, Vortex HT demonstrated slightly lower 
capture efficiencies than DFF (~85%) and the CTC-
iChip (~95% with negative depletion), but it adds several 
advantages. First, the device hastens downstream analyses 
with its ability to concentrate cells from any volume to 
~200 μL, suitable for immunostaining and quick imaging 
in a single well of a 96-well plate, whereas competing 
Oncotarget12755www.impactjournals.com/oncotarget
technologies must either scan across a large area of a glass 
slide [40] or perform a centrifugation and resuspension 
in a smaller volume [29], which may lose rare CTCs in 
the process. Next, Vortex HT maximizes throughput, 
operating at the highest known reported flow rate (8 mL/
min for ~80 mL of 10x diluted blood), compared with 
~100 μL/min for 10 mL of whole blood using the CTC-
iChip [40] and comparable to 350 μL/min for 3.75 mL 
of RBC-lysed blood using the modified high-throughput 
DFF [41]. Finally, the presented technology remains a 
top candidate in removing background cells, yielding half 
the number of WBCs as DFF [29] and over an order of 
magnitude greater purity than the CTC-iChip [40]. 
The high purity achieved with Vortex HT may 
facilitate CTC genotyping (sequencing, cytogenetics, 
etc.) in a step toward new drug discovery, personalized 
medicine, and informed treatment decisions for patients. 
Since cells also remain viable, Vortex HT enables other 
downstream analyses of live CTCs, including single-cell 
RT-PCR, cell culture, pharmacological studies [42], and 
single-cell Western blotting [43]. Moreover, the device 
provides a convenient sample preparation step that may be 
streamlined with cytopathology or immunocytochemistry 
techniques, in which technicians are often burdened by 
low sample purity. In addition to lung and breast cancer 
CTCs, the size-based isolation platform may potentially 
be applied for a variety of other cancer types (prostate, 
colon, melanoma, bladder cancer, etc.), or even other 
cell types (tumor cells, stem cells, endothelial cells, etc.) 
within a variety of biofluids (blood, urine, pleural [37] and 
peritoneal fluid, etc.).
The presence of atypical WBCs from a CML patient 
sample suggests that Vortex HT may also isolate large 
leukemic blasts. As CML cells range in size, with ~35% 
of cells in the range of 14-35 μm [44], Vortex HT may 
be effective in purifying rare subpopulations of large 
cells which may otherwise remain hidden from affinity-
based capture approaches. Although it remains unclear if 
the isolated cells are malignant cell precursors, immature 
white blood cells, or apoptotic cells, the absence of such 
cells from lung, breast, and healthy donor samples suggest 
their unique role in CML. These preliminary findings 
suggest further work is warranted to evaluate Vortex HT 
as an enrichment tool for a more sensitive identification of 
patient state that may be important for minimal residual 
disease monitoring. While relatively little microfluidic 
work has focused on sample preparation for observing 
and diagnosing CML, current techniques of isolation 
remain time-consuming or not fully developed [45]; 
Vortex HT may offer a high throughput, label-free means 
Figure 5: Comparison of Vortex HT with other technologies. A. Vortex HT captures more CTCs than the Vortex Chip in all cases 
(7 lung and 7 breast). B. Blood tubes from the same patient were split for tests between Vortex HT and CellSearch for 5 lung, 8 breast, and 
2 healthy samples. In two breast patients (no. 3 and 8, starred), the test was aborted by the CellSearch machine. C. In 13 of the metastatic 
cancer patient samples tested, the CellSearch test identified CTCs in 15% of samples, whereas Vortex HT found 85% of samples as positive 
for CTCs above levels for age-matched healthy controls.
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for leukemia cell purification. More broadly in a screening 
role, Vortex trapping from blood that yields an atypical 
large cell count may provide an earlier indication of a 
brewing disease process for a range of disease states [46], 
suggesting additional diagnostics to define the source of 
the large circulating cells may be warranted for the patient.
The objective cell identification criteria presented 
here addresses common but widely unreported concerns 
surrounding immunostains. Since many cells may 
transition to a mesenchymal state [32], traditional 
epithelial cell staining techniques may overlook a 
significant number of candidate cells [47], resulting in 
underreported performances especially in size-based 
isolation platforms. While most devices are characterized 
using probes for CK, CD45, and DAPI, the introduced 
CTC identification criteria makes use of a sequential 
checklist that includes well-defined morphological criteria 
associated with malignancy—which take advantage of 
accumulated cytopathology knowledge [10, 38, 39, 48]—
and may help minimize user-errors in manual enumeration. 
Morphological characterization may also help classify 
large cells that stain negative for common CTC markers, 
which may arise from size-based isolation methods, and 
cytometric analyses may sufficiently distinguish CTCs 
from other cell types present in blood, like monocytes, 
granulocytes, and cancer-associated non-CTCs such as 
disseminated tumor-activated macrophages [49]. We 
expect the described cell identification protocol will 
complement future device performance characterizations, 
clinical applications, and help standardize existing 
commercial prognostic and sample preparation tools as 
well as those in development. To help others who wish 
to adopt these tools, we provide a comprehensive guide 
and training worksheets (Supplementary Material) to more 
effectively convey our accumulated knowledge. As with 
most available techniques, the introduced enumeration 
protocol is not fully comprehensive and does not factor 
in the use of other marker types, including those that are 
cancer origin-specific (e.g., anti-HER2 staining for breast 
cancer samples, or anti-PSA for prostate cancer). We 
expect that the presented criteria will help foster future 
discussions regarding thorough validation of CTCs, and 
envision that the described criteria can serve as a starting 
point for further adaptations to the method as promising 
new markers or automated imaging software become 
available.
MATERIALS AND METHODS
Device operation and fabrication
Vortex technology is a 70 μm-depth 
polydimethylsiloxane (PDMS) device with an array of 
40 μm width straight channels, each leading to a series of 
500 μm x 720 μm rectangular trapping reservoirs, spaced 
1000 μm apart (Figure 1A). At a high flow rate, large cells 
experience large inertial shear gradient lift forces, migrate 
across streamlines, and become stably trapped in laminar 
fluid microvortices that develop in the reservoirs [36]. The 
relatively smaller blood cells do not experience a sufficient 
lift force to be stably trapped and may be washed away in 
a solution exchange that maintains cancer cell entrapment 
in vortices. By lowering the flow rate, vortices dissipate to 
release viable cells off chip in a concentrated volume in 
a well plate, glass slide, or microfuge tube (~150 μL per 
cycle) for downstream analysis. 
Conventional PDMS fabrication processes were 
used to assemble devices [50]. Briefly, microfluidic 
channel layouts were designed using AutoCAD (Autodesk 
Inc.) and printed on a 20,000 dpi photomask (CAD/Art 
Services, Inc.). A master mold was fabricated with the 
mask and standard photolithographic techniques using 
KMPR 1050 i-line photoresist (MicroChem Corp.) on a 
4-inch diameter silicon wafer (University Wafer, Inc.). 
PDMS was mixed in a 1:10 curing agent-to-base ratio, 
degassed, and cured over the mold at 65°C for 21 hours. 
PDMS was then cut, peeled from the wafer mold, and 
hole-punched (Syneo, LLC) before bonding to 3”x1” glass 
slides (VWR International LLC) using oxygen plasma 
(800 Micro RIE, Technics, Inc.) at 500 mTorr and 80 W 
RF power for 30 s.
Performance testing with cell lines
MCF7 breast cancer cells (ATCC) were used to 
characterize device efficiency. Cells were cultured in an 
incubator at 37°C and 5% CO
2
 with minimum essential 
medium supplemented with 10% fetal bovine serum, 
1% penicillin-streptomycin-glutamine, and 0.01 mg/mL 
human recombinant insulin (Gibco). Adherent cells were 
released with 0.25% (w/v) trypsin (Gibco), resuspended in 
media, assessed for concentration with a hemocytometer, 
and rocked gently on a shaker 30 min prior to experiments. 
Comparisons of efficiencies between devices were 
performed with the same batch of MCF7 cells, as cell size 
and deformability may fluctuate between passages and 
affect efficiency measurements. A target number of ~300 
cells was spiked in 4 mL of PBS or 10x diluted healthy 
blood and infused through the device. Flow was driven by 
the use of two syringe pumps (Harvard Apparatus), one 
for the sample solution and one for the wash solution. The 
device was initially primed with PBS wash solution at 8 
mL/min for 30 s. Wash solution flow rate was then reduced 
to 1 mL/min as sample solution was infused at 7 mL/min, 
totaling an 8 mL/min operational flow rate for cell capture. 
Solution exchange was performed by returning the wash 
solution flow rate back to 8 mL/min while stopping 
the sample syringe. Cells were released from vortices 
by stopping the flow from the wash solution briefly to 
dissipate the vortices and subsequently flushing the device 
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and tubing at a low flow rate. The enriched sample was 
released into a 96-well plate (Greiner CELLSTAR) for 
imaging and enumeration. Fluid waste was collected in 
a separate tube and reprocessed through the device for 
multiple cycles to increase capture, as specified in the 
results. To test viability, cells were spun down, incubated 
with media, and assayed with Calcein Blue AM and 
ethidium homodimer (Molecular Probes) every 24 hrs 
over the course of 4 days at which the experiment was 
stopped.
Staining and enumeration
Cells collected for enumeration were fixed in 2% 
paraformaldehyde (Electron Microscopy Sciences) for 10 
min, permeabilized in 0.4% v/v Triton X-100 (Research 
Products International Corp) for 7 min, blocked with 5% 
goat serum (Invitrogen) for 30 min, and stained with DAPI 
(Molecular Probes), anti CD45-phycoerythrin (CD45-
PE, Clone HI30, BD Biosciences), and a fluorescein 
isothiocyanate (FITC)-conjugated CK cocktail against 
Pan-CK AE1/AE3 (eBioscience), CK3-6H5 (Miltenyi 
Biotec), and CK CAM5.2 (BD Biosciences) for 40 
min at room temperature before imaging. The full 
staining protocol is included in Supplementary Material. 
Following CK staining, some samples were stained 
for granulocytes with CD66b-AlexaFluor647 (CD66b-
AF647, Clone G10F5, BD Biosciences), or for EMT 
markers with anti EpCAM-FITC (BD Biosciences), anti 
vimentin-AlexaFluor647 (VIM-AF647, Abcam), and anti 
N-Cadherin (NCAD-AF67, Abcam). Stitched images of 
stained wells were acquired at 100x magnification (Zeiss 
Axio Observer Z1 microscope with ZEN software and 
Photometrics CoolSnap HQ2 CCD camera), and cells 
were manually enumerated by 2 different persons who 
were blinded to avoid bias and subsequently established 
consensus. For tests with cell lines, capture efficiency 
was calculated as the number of captured target cells 
over the total number of target cells spiked into the initial 
sample. Purity was calculated as the number of target cells 
collected over the total number of captured nucleated cells. 
Clinical sample processing
Blood samples were acquired in two 10 mL EDTA-
coated tubes (Vacutainer, BD) from consenting stage IV 
lung and breast cancer patients collected from the UCLA 
Hematology and Oncology Santa Monica Clinic and 
Stanford Medical Center as well as from age-matched 
healthy donors following institutional review board 
approved protocols (UCLA IRB#11-001798 and Stanford 
IRB#5630). Within 4 hours of procurement, one tube of 
whole blood (~8 mL per sample) was diluted 10x in PBS 
(~80 mL of total volume) before processing through Vortex 
HT with 2 cycles, and enriched cells were collected in a 
96-well plate, immunostained, imaged, and enumerated. 
The second tube of blood from the same patient was either 
processed through the previous Vortex Chip [36] or sent 
for analysis by the gold standard CellSearch assay for 
breast cancer, serviced by Quest Diagnostics. All samples 
were de-identified by a clinical coordinator and research 
staff was blinded to the sample type (between lung, breast, 
or healthy blood samples). CTC counts from cancer 
samples were compared with the maximum enumerated 
value from healthy samples to determine which patients 
have tested positive for CTCs using Vortex HT.
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